Impact of genetic polymorphism in relation to other factors on expression and function of human drug-metabolizing P450s

Toxicology Mechanisms and Methods

Volumn 15, Issue 2, 2005, Pages 121-124

  Zanger, Ulrich M ^a,b   Klein, Kathrin ^a   Richter, Tanja ^a   Toscano, Claudia ^a   Zukunft, Jörg ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b Institute of Clinical Genetics   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; ISOENZYME; PHENOBARBITAL;

ARTICLE; CONTROLLED STUDY; DNA SPLICING; DOWN REGULATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; GENE EXPRESSION REGULATION; GENE EXPRESSION SYSTEM; GENE FREQUENCY; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC REGULATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; LIVER; PHENOTYPE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; SEX DIFFERENCE; WESTERN BLOTTING;

RODENTIA; STAPHYLOCOCCUS PHAGE 3A;

EID: 18344369897     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.1080/15376520590918847     Document Type: Article

References (16)

1. Burk, O., Tegude, H., Koch, I., Hustert, E., Wolbold, R., Glaeser, H., Klein, K., Fromm, M. F., Nuessler, A., K., Neuhaus, P., Zanger, U. M., Eichelbaum, M., and Wojnowski, L. 2002. Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J. Biol. Chem. 277:24280-24288.
2. Eiselt, R., Domanski, T. L., Zibat, A., Mueller, R., Presecan-Siedel, E., Hustert, E., Zanger, U. M., Brockmoller, J., Klenk, H. P., Meyer, U. A., Khan, K. K., He, Y. A., Halpert, J. R., and Wojnowski, L. 2001. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11:447-458.
3. Endrizzi, K., Fischer, J., Klein, K., Schwab, M., Nussler, A. K., Neuhaus, P., Eichelbaum, M., and Zanger, U. M. 2002. Discriminative quantification of cytochrome P4502D6 and 2D7/8 pseudogene expression by TaqMan real-time reverse transcriptase polymerase chain reaction. Anal. Biochem. 300:121-131.
4. Griese, E. U., Zanger, U. M., Brudermanns, U., Gaedigk, A., Mikus, G., Morike, K., Stuven, T., and Eichelbaum, M. 1998. Related assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8:15-26.
5. Hustert, E., Haberl, M., Burk, O., Wolbold, R., He, Y. Q., Klein, K., Nuessler, A. K., Neuhaus, P., Klattig, J., Eiselt, R., Koch, I., Zibat, A., Brockmoller, J., Halpert, J. R., Zanger, U. M., and Wojnowski, L. 2001. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773-779.
6. Ingelman-Sundberg, M., Daly, A. K., and Neben, D. W. 2004. The CYP allele nomenclature homepage: http://imm.ki.se/CYPalleles/
7. Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M. L., and Ingelman-Sundberg, M. 1996. PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 6:351-355.
8. Koch, I., Weil, R., Wolbold, R., Brockmoller, J., Hustert, E., Burk, O., Nuessler, A., Neuhaus, P., Eichelbaum, M., Zanger, U., and Wojnowski, L. 2002. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab. Dispos. 30:1108-1114.
9. Kuehl, P. et al. 2001. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27:383-391.
10. Lang, T., Klein, K., Fischer, J., Nüssler, A. K., Neuhaus, P., Hofmann, U., Eichelbaum, M., Schwab, M., and Zanger, U. M. 2001. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399-415.
11. Lang, T., Klein, K., Richter, T., Zibat, A., Kerb, R., Eichelbaum, M., Schwab, M., and Zanger, U. M. 2004. Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J. Pharmacol. Exp. Ther. 311:34-43.
12. Raimundo, S., Fischer, J., Eichelbaum, M., Griese, E.-U., Schwab, M., and Zanger, U. M. 2000. Elucidation of the genetic basis of the common "intermediate metabolizer" phenotype for drug oxidation by CYP2D6. Pharmacogenetics 10:577-581.
13. Raimundo, S., Toscano, C., Klein, K., Fischer, J., Griese, E. U., Eichelbaum, M., Schwab, M., and Zanger, U. M. 2004. A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin. Pharmacol. Ther. 76:128-138.
14. Wolbold, R., Klein, K., Burk, O., Nüssler, A. K., Neuhaus, P., Eichelbaum, M., Schwab, M., and Zanger, U. M. 2003. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 8:978-988.
15. Zanger, U. M., Fischer, J., Klein, K., and Lang, T. 2002. Detection of single nucleotide polymorphisms in CYP2B6 gene. Methods Enzymol. 357:45-53.
16. Zanger, U. M., Fischer, J., Raimundo, R., Stüven, T., Evert, B. O., Schwab, M., and Eichelbaum, M. 2001. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11:573-585.